Bahram Valamehr
Board Member
Fate Therapeutics Inc (FATE)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Bahram Valamehr
Bahram Valamehr is recorded as CEO and Board Member at Fate Therapeutics Inc (FATE). Fate Therapeutics Inc reported in an 8-K filed November 29, 2024 that Bahram Valamehr was appointed director, effective January 1, 2025. Fate Therapeutics Inc reported in an 8-K filed November 29, 2024 that Bahram Valamehr was appointed President and CEO, effective January 1, 2025. The proxy statement of Fate Therapeutics Inc reports total compensation of $2,248,568 for Bahram Valamehr in fiscal 2025, including a base salary of $600,000. Disclosed compensation is on record for 7 fiscal years.
“Bahram Valamehr, Ph.D., MBA will succeed Mr. Wolchko as a director and as the Company's President and CEO (and as the Company's principal executive officer, principal financial officer and principal accounting officer), effective as of January 1, 2025.”
“Bahram Valamehr, Ph.D., MBA will succeed Mr. Wolchko as a director and as the Company's President and CEO (and as the Company's principal executive officer, principal financial officer and principal accounting officer), effective as of January 1, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
-
Current
Start not stated–present
-
Fate Therapeutics Inc (FATE)
Proxy statement
Start not stated–2024-04-26
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Fate Therapeutics Inc
Other people whose current roles at this company are on record from its filings.
- Scott Wolchko CEO, Board Member
- William H. Rastetter Chairman
- J. Scott Wolchko CFO, Chief Accounting Officer
- Kamal Adawi CFO, Chief Accounting Officer
- Cindy R. Tahl General Counsel
- Edward J. Dulac III Chief Accounting Officer
- Karin Jooss Board Member
- Karin Jooss, Ph.D. Board Member
- Laura J. Hamill Board Member
- Matthew Abernethy Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Fate Therapeutics Inc (FATE) | Ph.D., MBA President, Chief Executive Officer and Director | $600,000 | $2,248,568 |
| 2024 | Fate Therapeutics Inc (FATE) | Ph.D., MBA President, Chief Executive Officer and Director | $525,000 | $3,584,600 |
| 2023 | Fate Therapeutics Inc (FATE) | Chief Research and Development Officer | $500,000 | $2,986,615 |
| 2022 | Fate Therapeutics Inc (FATE) | Chief Research and Development Officer | $455,000 | $3,157,751 |
| 2021 | Fate Therapeutics Inc (FATE) | Chief Research and Development Officer | $430,000 | $6,477,416 |
| 2019 | Fate Therapeutics Inc (FATE) | Chief Development Officer | $375,000 | $2,818,586 |
| 2018 | Fate Therapeutics Inc (FATE) | Chief Development Officer | $321,865 | $2,577,350 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.